The 2024/25 influenza season in Europe is currently characterised by co-circulation of influenza A(H1N1) pdm09, A(H3N2) and B/Victoria viruses, with influenza A(H1N1)pdm09 predominating. Interim vaccine effectiveness (VE) estimates from eight European studies (17 countries) indicate an all-age influenza A VE of 32–53% in primary care and 33–56% in hospital settings, with some signals of lower VE by subtype and higher VE against influenza B (≥ 58% across settings). Where feasible, influenza vaccination should be encouraged and other prevention measures strengthened.
10.2807/1560-7917.ES.2025.30.7.2500102
Journal article
2025-02-20T00:00:00+00:00
30
9 - 19
10